Scientific deep-dive

Tirzepatide vs Semaglutide: A Head-to-Head Look at SURMOUNT and STEP

What the SURMOUNT and STEP trial families actually tell us about which GLP-1 drug produces more weight loss, fewer side effects, and longer-lasting results.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
13 min read·17 citations

This head-to-head comparison is part of Weight Loss Rankings' living editorial database — 1,160+ research articles and 630+ editorially reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

Semaglutide (Wegovy) and tirzepatide (Zepbound) are the two injectable weight-loss medications most patients are choosing between in 2026. They're mechanistically similar — both are once-weekly subcutaneous injections that target the body's incretin pathways — but they aren't the same drug, and the trial evidence comparing them is now substantial enough to say meaningful things about which one works better, for whom, and at what cost.

This piece walks through the head-to-head and parallel trial data from the STEP family (semaglutide) and the SURMOUNT family (tirzepatide), then layers on the side effect profile, discontinuation rates, and the cost-per-pound calculation that most patients actually need to make a real decision.

Where to buy compounded tirzepatide — top vetted providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $69/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $129/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $129/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $179/mo (prepaid plan rate)

Get started →Read review Gala →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Starting price: $239/mo (12-month plan rate)

Get started →Read review Found →

Mechanism: a single agonist vs a dual agonist

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the gut hormone GLP-1, which is released in response to eating and produces several effects relevant to weight: it slows gastric emptying, increases satiety signaling in the brain, and improves insulin secretion in response to glucose.[1]

Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is a sister incretin hormone with overlapping but distinct effects on appetite, energy expenditure, and adipose tissue metabolism. The combination produces measurably stronger effects on weight and glucose control in trials than GLP-1 agonism alone, and it's the reason tirzepatide outperforms semaglutide on most weight-loss endpoints in head-to-head data.[10][5]

Whether GIP's contribution is purely additive or whether it enables novel mechanisms (changes in adipose tissue insulin sensitivity, increased energy expenditure) is still a live research question. What's clear from the trials: the dual agonist consistently produces more weight loss at any given dose equivalence point.

The headline trial results

The cleanest comparison is between STEP 1 (semaglutide 2.4 mg weekly, 68 weeks, n=1,961) and SURMOUNT-1 (tirzepatide 5/10/15 mg weekly, 72 weeks, n=2,539). Both enrolled adults with overweight or obesity but without type 2 diabetes, both used the same lifestyle intervention background, and both used what were then the highest labeled doses for the weight-loss indication (Wegovy has since added a 7.2 mg adult maximum).[3][4]

At the highest dose each trial tested:

  • Semaglutide 2.4 mg: mean weight loss of −14.9% at 68 weeks (STEP-1 treatment-regimen estimand, the primary ITT-style published value). About 30% of patients reached ≥20% body weight loss (30.2% versus 1.7% on placebo in the label's treatment-regimen analysis).[15]
  • Tirzepatide 15 mg: mean weight loss of −20.9% at 72 weeks (SURMOUNT-1 treatment-regimen estimand, the primary published value; the lower 5 mg and 10 mg doses produced −15.0% and −19.5% respectively). About 57% of patients on 15 mg reached ≥20% body weight loss.

That's roughly a 6 percentage point absolute difference, which translates to about 40% more weight loss on tirzepatide than semaglutide 2.4 mg. The difference is large, it's statistically robust, and it has held up across subsequent trial replications.

A note on estimands. Both of the numbers above are the FDA-approved primary “treatment-regimen” estimand — the ITT-equivalent that includes all randomized participants regardless of whether they stayed adherent to the drug. The published “efficacy estimand” (on-treatment, adherent population) is somewhat higher for both drugs: −16.9% for semaglutide 2.4 mg in STEP-1, and −16.0% / −21.4% / −22.5% at the 5/10/15 mg tirzepatide doses in SURMOUNT-1, per the STEP-1 results posted on ClinicalTrials.gov and the SURMOUNT-1 paper.[17][4] The headline “22.5% vs 14.9%” comparison you'll see quoted in many places mixes a tirzepatide efficacy estimand with a semaglutide treatment-regimen estimand, which isn't an apples-to-apples comparison. When comparing GLP-1s, always use the same estimand for both drugs. We use the treatment-regimen values throughout this article because that's the primary estimand on both the Wegovy and Zepbound FDA labels.

SURMOUNT-5 — the first true head-to-head trial — confirmed this. Published in 2025, SURMOUNT-5 randomized 751 adults with obesity directly to tirzepatide or semaglutide at maximum tolerated doses for 72 weeks. Tirzepatide produced a mean weight loss of about 20.2% versus 13.7% for semaglutide, a 6.5 point absolute difference. Tirzepatide also came out ahead on the key secondary endpoints: waist circumference fell 18.4 cm versus 13.0 cm, and more people on tirzepatide reached at least 10%, 15%, 20% and 25% weight loss.[5]

Magnitude comparison

Weight-loss magnitude across the pivotal trials — SURMOUNT-5 head-to-head (the first direct randomized comparison) alongside the parallel STEP-1 and SURMOUNT-1 monotherapy trials. All values are %TBWL at trial endpoint on the treatment-regimen estimand.[3][4][5]

  • Semaglutide 2.4 mg — SURMOUNT-5 head-to-head (72 wk)13.7 % TBWL
  • Tirzepatide max dose — SURMOUNT-5 head-to-head (72 wk)20.2 % TBWL
    +6.5 pp absolute advantage over semaglutide in the same trial
  • Semaglutide 2.4 mg — STEP-1 (68 wk, parallel)14.9 % TBWL
  • Tirzepatide 15 mg — SURMOUNT-1 (72 wk, parallel)20.9 % TBWL
Weight-loss magnitude across the pivotal trials — SURMOUNT-5 head-to-head (the first direct randomized comparison) alongside the parallel STEP-1 and SURMOUNT-1 monotherapy trials. All values are %TBWL at trial endpoint on the treatment-regimen estimand.

Side effect profile

Both drugs share the GI side effect profile that's characteristic of GLP-1 agonism: nausea, vomiting, diarrhea, constipation. The pooled rates are higher than placebo for both, and meaningfully different between the two only in degree.

The pooled adverse-reaction tables on the FDA labels (Wegovy 2.4 mg across three STEP trials; Zepbound 15 mg across SURMOUNT-1 and SURMOUNT-2) look like this:[15][16]

  • Nausea: 44% on semaglutide, 28% on tirzepatide 15 mg. Most events are mild to moderate and concentrated in the dose-escalation period.
  • Vomiting: 24% semaglutide, 13% tirzepatide.
  • Diarrhea: 30% semaglutide, 23% tirzepatide.
  • Constipation: 24% semaglutide, 11% tirzepatide 15 mg (17% on 5 mg).
  • Serious adverse events: 9.8% on semaglutide versus 6.4% on placebo in STEP 1, per its posted results.[17] We could not confirm a matching 72-week figure for SURMOUNT-1, so we leave it out.

The somewhat surprising pattern: tirzepatide actually had lower rates of upper-GI symptoms (nausea, vomiting) than semaglutide in the trials, despite producing more weight loss. The leading hypothesis is that GIP receptor activation has a separate anti-emetic effect that partially counteracts the nausea induced by GLP-1 agonism. This is one of the more intriguing pharmacology stories in the field.[6]

Discontinuation rates

Discontinuation is the metric that matters most in real clinical practice, because the high trial completion rates can hide how many people stayed on a lower dose than planned for tolerability. In the trials:

  • Semaglutide 2.4 mg (STEP trials pooled on the Wegovy label): 6.8% stopped treatment for adverse reactions, vs 3.2% on placebo.[15]
  • SURMOUNT-1 tirzepatide 15 mg: 6.2% discontinued for adverse events, vs 2.6% on placebo.

Real-world data is messier and shows much higher attrition. A 2024 commercial-claims analysis of 4,066 US adults without diabetes who started a GLP-1 for obesity in 2021 found that only 32.3% were still on therapy at one year, so roughly two in three had stopped — far higher than the trial dropout rates. Because the cohort started before tirzepatide was approved for weight loss, it mostly reflects semaglutide and liraglutide. Pharmacy claims show when people stop, not why, so this study does not report reasons for stopping.[7]

In the same cohort, 46.3% were still on therapy at 180 days, so much of the stopping happened in the first six months. That early stretch is also the dose escalation window.

Cardiovascular and metabolic outcomes

Trial data on hard cardiovascular outcomes is more mature for semaglutide than for tirzepatide, simply because semaglutide has been on the market longer. The SELECT trial (2023) showed a 20% relative risk reduction for major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and overweight/obesity but without diabetes. That's the strongest evidence in the field that the cardiovascular benefits of GLP-1 weight loss are real and durable.[8]

Tirzepatide's cardiovascular outcomes trial — SURPASS-CVOT, a head-to-head against dulaglutide in patients with type 2 diabetes — was published in 2025 showing non-inferiority for MACE. The dedicated tirzepatide-for-obesity cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing, with results expected in 2027. Until that reads out, the assumption in the field is that the dual agonist will produce at least as much cardiovascular benefit as the GLP-1-only drug, but the formal evidence base is currently smaller.[9]

Both drugs produce roughly equivalent improvements in fasting glucose, HbA1c, blood pressure, triglycerides, and liver enzymes. For patients with type 2 diabetes specifically, tirzepatide's edge on glucose control is more pronounced — the SURPASS trials showed superior HbA1c reductions head-to-head against semaglutide in diabetic populations.[10]

The cost-per-pound calculation

The interesting question for most patients isn't which drug produces more weight loss in a trial — it's which one produces the best value, given what they'll actually pay out of pocket.

For a hypothetical 220-pound patient:

  • Brand-name Wegovy at $349/month NovoCare self-pay, producing 14.9% weight loss (about 33 pounds) over 68 weeks: roughly $5,460 in total, or about $167 per pound lost.
  • Brand-name Zepbound at $449/month LillyDirect self-pay at the 10–15 mg doses, producing 20.9% weight loss (about 46 pounds) over 72 weeks: roughly $162 per pound lost.
  • Compounded semaglutide at the median ~$150/month, same trial efficacy assumption: roughly $72 per pound lost.
  • Compounded tirzepatide at the median ~$300/month: roughly $108 per pound lost.

The compounded forms reverse the cost ranking: semaglutide is actually cheaper per pound on a cash-pay basis, even though tirzepatide produces more total weight loss, because compounded tirzepatide remains roughly 2x the price of compounded semaglutide. For patients optimizing pure cost-per-result, that flip is the most important practical takeaway from this whole comparison.

Caveat: these calculations assume trial efficacy translates to real-world results, which is generous. Real-world weight loss is usually lower than trial weight loss because patients don't complete the same dose escalation, miss more doses, and have less structured lifestyle support. But the relative ranking holds.

Who should pick which

Working through the trial data and the cost calculations, here's how the choice tends to shake out for different patient profiles:

  • Higher BMI (40+) seeking maximum weight loss: tirzepatide. The ~6 point absolute weight-loss advantage is larger in absolute terms when you have more weight to lose, and the cost differential matters less proportionally.
  • Type 2 diabetes plus obesity: tirzepatide. The glucose control advantage in the SURPASS trials is meaningful, and tirzepatide was approved for type 2 diabetes (as Mounjaro) before its weight-management indication.
  • Lower BMI (27–32) needing 10–15% loss to hit a goal: semaglutide. You don't need the extra horsepower, and you'll save substantially on cost.
  • Established cardiovascular disease without diabetes: currently semaglutide, on the strength of SELECT. This may change once SURMOUNT-MMO reads out for tirzepatide in 2027.
  • History of severe GI sensitivity or prior GLP-1 intolerance: tirzepatide is worth trying given the lower nausea and vomiting rates — but expect to start slow regardless of which one.
  • Cost is the deciding factor: compounded semaglutide remains the lowest cost-per-pound option in the market, by a meaningful margin.

Ready to start? Top vetted GLP-1 providers by editorial score

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Starting price: $149/mo (+ required membership)

Get started →Read review Ro →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →

What we'll be watching in 2026–2027

The two big readouts that should change how this comparison looks:

  • SURMOUNT-MMO: the dedicated tirzepatide cardiovascular outcomes trial in patients with obesity but without diabetes. If positive (which seems likely), it eliminates the last major reason to default to semaglutide for patients with cardiovascular risk.
  • Oral semaglutide for weight: oral semaglutide began as Rybelsus at low doses for diabetes. In OASIS 1, a 50 mg daily dose produced 15.1% weight loss at 68 weeks, comparable to injectable semaglutide, and the FDA approved the Wegovy pill (oral semaglutide 25 mg) for weight management on December 22, 2025 — a real shift in the convenience calculus.[11]
  • Triple agonists (retatrutide). Eli Lilly's triple GLP-1/GIP/glucagon agonist showed mean weight loss of 24.2% at 48 weeks in phase 2.[12] The phase 3 results are now published. In TRIUMPH-1 (obesity, no diabetes), the 12 mg dose cut body weight by 25.0% at 80 weeks, versus 3.9% on placebo.[13] In TRIUMPH-2, adults with obesity and type 2 diabetes lost 18.8% at 80 weeks on 12 mg, versus 5.1% on placebo.[14] Retatrutide is not FDA-approved yet. If it is approved, the competitive picture changes.

Until those readouts, the practical answer for most patients remains the one above: tirzepatide for maximum effect, semaglutide for maximum value, and the compounded forms of either for meaningful cost savings against brand. If you have settled on the dual agonist, our shortlist of top tirzepatide providers ranks where to start; the full comparison across every provider in our dataset is on our compare page.

Related research

The head-to-head efficacy comparison above is one of several editorial deep dives we maintain on this drug class. For readers who want the full picture beyond the weight-loss primary endpoint:

Further reading

References

  1. 1.Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019. PMID: 31767182.
  2. 2.Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021. PMID: 34186022.
  3. 3.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  4. 4.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  5. 5.Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. PMID: 40353578.
  6. 6.Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020. PMID: 32396843.
  7. 7.Gleason PP, Urick BY, Marshall LZ, Friedlander N, Qiu Y, Leslie RS. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. J Manag Care Spec Pharm. 2024. PMID: 38717042.
  8. 8.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
  9. 9.Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). N Engl J Med. 2025. PMID: 41406444.
  10. 10.Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide Versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  11. 11.Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023. PMID: 37385278.
  12. 12.Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315.
  13. 13.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
  14. 14.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
  15. 15.Novo Nordisk WEGOVY (semaglutide) injection and tablets, prescribing information (Table 3, adverse reactions). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  16. 16.Eli Lilly and Company ZEPBOUND (tirzepatide) injection, prescribing information (Table 1, adverse reactions). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  17. 17.Novo Nordisk STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (NCT03548935), posted results. ClinicalTrials.gov. 2022. https://clinicaltrials.gov/study/NCT03548935

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Frequently Asked Questions

Tirzepatide produces approximately 40% more weight loss than semaglutide at the highest doses tested in SURMOUNT-1 and STEP 1. SURMOUNT-1 (Jastreboff NEJM 2022) reported -20.9% body weight on tirzepatide 15 mg over 72 weeks; STEP-1 (Wilding NEJM 2021) reported -14.9% on semaglutide 2.4 mg over 68 weeks. The mechanism difference is real: tirzepatide is a dual GIP + GLP-1 receptor agonist, while semaglutide is a single GLP-1 receptor agonist.
Wegovy and Ozempic are both semaglutide; Zepbound and Mounjaro are both tirzepatide. Within each pair, the only meaningful differences are the FDA-approved indication and the dosing strength. Wegovy is FDA-approved for chronic weight management at doses up to 7.2 mg/week (2.4 mg is the recommended maintenance dose); Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg/week. Same drug, different label. Zepbound and Mounjaro have the same relationship for tirzepatide.
Counterintuitively, no. The SURMOUNT-1 and STEP-1 adverse event tables show broadly similar GI side effects for tirzepatide 15 mg and semaglutide 2.4 mg, and tirzepatide actually had LOWER nausea rates: 28% on Zepbound 15 mg versus 44% on Wegovy 2.4 mg in the pooled FDA label tables. Discontinuation rates due to adverse events were similar (~6-7%) across both drugs in their respective trials.
Tirzepatide is more expensive per month but more efficient per pound lost. Brand-name Zepbound through LillyDirect is $299-449/month dose-tiered when refilled on time ($699 regular price at the top doses); Wegovy NovoCare is $199-399/month. Per pound lost, the calculation depends on how much weight each patient loses, but for the trial-average patient tirzepatide produces more total weight loss for similar monthly cost, making it slightly cheaper per pound. Use our cost-per-pound calculator for personalized math.
Yes, with appropriate clinical oversight. Switching requires re-titration to start at the lowest tirzepatide dose (2.5 mg/week) regardless of your current semaglutide dose. The full titration to 15 mg takes about 5 months. There is no formal washout period required because both drugs work via overlapping pathways. Discuss switching with your prescribing clinician.

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $129/mo (sale price)

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $179/mo (prepaid plan rate)

Get started →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

From $239/mo (12-month plan rate)

Get started →